Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
Combinatie van doelgerichte therapieën bij gerecidiveerd diffuus grootcellig B-cellymfoom
sep 2024 | Lymfoom